Andries H Groen1, Thomas H Beckham2, Thera P Links3, Debra A Goldman4, Eric J Sherman5, Michael M Tuttle5, Hendrik P Bijl6, Richard J Wong7, John Th M Plukker1, Nancy Y Lee2. 1. Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Medicine, Endocrine Service, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: We evaluated the outcomes of surgery with or without postoperative radiation therapy (PORT) in the management of medullary thyroid carcinoma (MTC). METHODS: From two tertiary cancer centers, 297 consecutive patients with MTC treated with PORT (n = 46) between 1990 and 2016 or surgery alone (n = 251) between 2000 and 2016 were reviewed. RESULTS: Ten-year cumulative incidences of locoregional and distant failure were 30.2% and 24.9% in the surgery cohort, and 16.9% and 55.2% in the PORT cohort. In the surgery alone cohort, T4 disease, extrathyroidal extension, N1 disease, extranodal extension (ENE), and residual disease after surgery were associated with local failure. The PORT cohort had significantly higher proportions of patients with T4 disease, N1 disease, ENE, and residual disease. CONCLUSIONS: High-risk clinical features can help identify patients with MTC at high-risk for local failure after surgery alone. Patients with high-risk clinical features had effective locoregional control after PORT.
BACKGROUND AND OBJECTIVES: We evaluated the outcomes of surgery with or without postoperative radiation therapy (PORT) in the management of medullary thyroid carcinoma (MTC). METHODS: From two tertiary cancer centers, 297 consecutive patients with MTC treated with PORT (n = 46) between 1990 and 2016 or surgery alone (n = 251) between 2000 and 2016 were reviewed. RESULTS: Ten-year cumulative incidences of locoregional and distant failure were 30.2% and 24.9% in the surgery cohort, and 16.9% and 55.2% in the PORT cohort. In the surgery alone cohort, T4 disease, extrathyroidal extension, N1 disease, extranodal extension (ENE), and residual disease after surgery were associated with local failure. The PORT cohort had significantly higher proportions of patients with T4 disease, N1 disease, ENE, and residual disease. CONCLUSIONS: High-risk clinical features can help identify patients with MTC at high-risk for local failure after surgery alone. Patients with high-risk clinical features had effective locoregional control after PORT.
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Hans H G Verbeek; Johannes A A Meijer; Wouter T Zandee; Kelvin H Kramp; Wim J Sluiter; Johannes W Smit; Job Kievit; Thera P Links; John Th M Plukker Journal: Ann Surg Oncol Date: 2014-10-15 Impact factor: 5.344
Authors: E Modigliani; R Cohen; J M Campos; B Conte-Devolx; B Maes; A Boneu; M Schlumberger; J C Bigorgne; P Dumontier; L Leclerc; B Corcuff; I Guilhem Journal: Clin Endocrinol (Oxf) Date: 1998-03 Impact factor: 3.478
Authors: Marta Kaczmarek-Ryś; Katarzyna Ziemnicka; Andrzej Pławski; Bartłomiej Budny; Michał Michalak; Szymon Hryhorowicz; Justyna Hoppe-Gołębiewska; Paweł Boruń; Monika Gołąb; Małgorzata Czetwertyńska; Maria Sromek; Marlena Szalata; Marek Ruchała; Ryszard Słomski Journal: Endocr Relat Cancer Date: 2018-01-31 Impact factor: 5.678
Authors: Thomas H Beckham; Paul B Romesser; Andries H Groen; Christopher Sabol; Ashok R Shaha; Mona Sabra; Thomas Brinkman; Daniel Spielsinger; Sean McBride; C Jillian Tsai; Nadeem Riaz; R Michael Tuttle; James A Fagin; Eric J Sherman; Richard J Wong; Nancy Y Lee Journal: Thyroid Date: 2018-09 Impact factor: 6.568